Relay Total Stockholder Equity from 2010 to 2025

RLAY Stock  USD 4.54  0.06  1.34%   
Relay Therapeutics Total Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Total Stockholder Equity will likely drop to about 563.2 M in 2025. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2019-12-31
Previous Quarter
681.7 M
Current Value
838.9 M
Quarterly Volatility
329.4 M
 
Covid
Check Relay Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Relay Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 37.5 M, Interest Income of 37.5 M or Depreciation And Amortization of 4 M, as well as many indicators such as Price To Sales Ratio of 45.17, Dividend Yield of 0.0 or PTB Ratio of 1.0. Relay financial statements analysis is a perfect complement when working with Relay Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Relay Therapeutics Correlation against competitors.
For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.

Latest Relay Therapeutics' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Relay Therapeutics over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Relay Therapeutics' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Relay Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Slightly volatile
   Total Stockholder Equity   
       Timeline  

Relay Total Stockholder Equity Regression Statistics

Arithmetic Mean225,783,535
Geometric Mean238,477,377
Coefficient Of Variation206.15
Mean Deviation429,577,044
Median(110,927,000)
Standard Deviation465,461,658
Sample Variance216654.6T
Range1.1B
R-Value0.80
Mean Square Error84250T
R-Squared0.64
Significance0.0002
Slope78,033,132
Total Sum of Squares3249818.3T

Relay Total Stockholder Equity History

2025563.2 M
2024864.8 M
2023752 M
2022950.2 M
2021897.8 M
2020763.3 M
2019-180.4 M

About Relay Therapeutics Financial Statements

Relay Therapeutics investors use historical fundamental indicators, such as Relay Therapeutics' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Relay Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Stockholder Equity864.8 M563.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.